- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Entera Bio Ltd(ENTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ENTX
11/20/2026: ENTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Entera Bio Ltd is a clinical-stage biopharmaceutical company that develops oral tablet formulations of peptide and protein replacement therapies using its proprietary delivery platform. The company's primary strength lies in its innovative oral technology and lead candidate EB613 for osteoporosis, which offers a convenient alternative to traditional injections. Its main growth opportunity centers on expanding this platform into lucrative metabolic conditions like obesity alongside strategic industry partners. However, the company faces significant execution, regulatory, and financing risks given its pre-revenue status and high cash burn profile. The stock suits speculative growth investors willing to tolerate high volatility in exchange for potential clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high potential upside tied to clinical breakthroughs, but lacks commercial revenue growth today. |
| Momentum investor | Strong fit while signal remains positive | Trades actively around clinical trial updates and biotech sector catalysts, making it attractive during positive momentum uptturns. |
| Value investor | Weak fit | Lacks earnings, P/E ratios, and positive cash flows, rendering traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Does not pay dividends and retains all capital for clinical research. |
| Low-risk investor | Weak fit | High clinical, regulatory, and price volatility risks make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks experience sharp price swings based on trial data and financing announcements. |
| Valuation risk | High | With negligible revenue, valuations rely entirely on speculative future commercial potential. |
| Competition risk (large pharmaceutical incumbents) | High | Well-funded competitors can out-scale or out-market alternative therapies. |
| Business quality | Medium | Proprietary technology is robust, but commercial validation is unproven. |
| Dividend income | Low / none | No payouts are provided to investors. |
| Execution risk | High | Success depends on complex clinical trials and regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 571.17M USD | Price to earnings Ratio - | 1Y Target Price 9.75 |
Price to earnings Ratio - | 1Y Target Price 9.75 | ||
Volume (30-day avg) 401.9K shares | Beta 1.46 | 52 Weeks Range 0.91 - 4.20 | Updated Date 11/20/2026 |
52 Weeks Range 0.91 - 4.20 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 38.86% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research Collaborations & Grants | Early-stage development fees, research services, and grant funding from partnership agreements. | The company generates minimal revenue currently, functioning entirely as a pre-commercial research enterprise. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 303.94M | Price to Sales(TTM) - |
Enterprise Value 303.94M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 452.96 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 174.14M | Shares Floating 107.29M |
Shares Outstanding 174.14M | Shares Floating 107.29M | ||
Percent Insiders 5.42 | Percent Institutions 80.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

